Linked Life Data

9499549

Source:http://linkedlifedata.com/resource/pubmed/id/9499549

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1998-4-17
pubmed:abstractText
The relationship between thromboembolism and oral contraceptives has been discussed for 30 years. Recently, a new actuality for this problem has grown up. The estrogen component of the preparations seems to be the cause, but some authors also think of the progestogens as responsible for drug-related thromboembolic disorders. In 31 patients with mastopathy or mastodynia, who had been treated with 10 mg medrogeston of dydrogesteron for six cycles, there were no significant changes in the parameters of hemostasis and fibrinolysis. Especially, we did not find any indications to an activation of the coagulation system. There is no evidence for a thrombogenetic effect caused by the cyclic therapy with these progestogens.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0044-4197
pubmed:author
pubmed:issnType
Print
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
32-7
pubmed:dateRevised
2008-2-11
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
[The effect of cyclic administration of progestagens on blood coagulation factors].
pubmed:affiliation
Abteilung für Gynäkologie/gynäkologische Onkologie, Universitätsklinikum Essen.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, English Abstract